drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An IgG1 monoclonal antibody targeting Claudin 18.2 (CLDN18.2) on gastric/GEJ tumor cells, mediating immune effector functions including Fcγ receptor–driven antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and potential antibody-dependent cellular phagocytosis (ADCP).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Zolbetuximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
A tumor-targeting IgG1 monoclonal antibody that binds Claudin 18.2 on gastric/GEJ cancer cells and induces immune-mediated killing via Fcγ receptor–dependent ADCC, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).
drug_name
Zolbetuximab (IMAB362)
nct_id_drug_ref
NCT06767449